Last reviewed · How we verify
NERATINIB MALEATE
NERATINIB MALEATE is a drug. It is currently FDA-approved (first approved 2017).
At a glance
| Generic name | NERATINIB MALEATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2017 |
Approved indications
Common side effects
Key clinical trials
- Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene (PHASE1)
- Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test (PHASE1, PHASE2)
- Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers (PHASE2)
- Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases (PHASE2)
- Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NERATINIB MALEATE CI brief — competitive landscape report
- NERATINIB MALEATE updates RSS · CI watch RSS
Frequently asked questions about NERATINIB MALEATE
What is NERATINIB MALEATE?
NERATINIB MALEATE is a Small molecule drug.
When was NERATINIB MALEATE approved?
NERATINIB MALEATE was first approved on 2017.
What development phase is NERATINIB MALEATE in?
NERATINIB MALEATE is FDA-approved (marketed).
Related
- Compare: NERATINIB MALEATE vs similar drugs
- Pricing: NERATINIB MALEATE cost, discount & access